Saturday, February 27, 2021
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
    • All Events
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
    • All Events
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

DARPA Award to Agentase for Wearable CBRN Surveillance Suits

by Global Biodefense Staff
April 7, 2014

The Defense Advanced Research Projects Agency (DARPA) recently announced intentions to award a sole source contract to Agentase LLC (a FLIR Systems company) for the Agent-exposure Surveillance & Protection Integrated Suits (ASPIS) project.

The goal of ASPIS is to provide novel coatings to deliver colorimetric detection methods in both the visible and NIR that respond to sub-microgram exposure to G- and V-series nerve agents, integrated into personal protective equipment (PPE). Moreover, these coatings will hydrolyze nerve agents on PPE to reduce or eliminate the contact hazard posed to personnel when PPE is removed.

The contract will leverage both the company’s recent advances in enzymatic detection technologies, as well as complementary research they are conducting in support of DARPA’s In Vivo Nanoplatforms program (IVN) program (FLIR Contract No. HR0011-14-C-0030), which seeks to develop new classes of adaptable nanoparticles for persistent, distributed, unobtrusive physiologic and environmental sensing as well as the treatment of physiologic abnormalities, illness and infectious disease.

It is envisioned that the project will, within 15 months, result in prototype self-disclosing and self-decontaminating coating technologies to the warfighter that will enhance the protective value of PPE.

Existing FLIR products have already demonstrated the integration of G-series hydrolyzing enzymes with pH reactive dyes to reveal agent exposure at the sub-microgram level on multiple surface types. The company has also demonstrated persistent, stable coatings under the Defense Threat Reduction Agency (DTRA) Hazard Mitigation, Materiel, and Equipment Restoration Advanced Technology Demonstration (HaMMER ATD, 2010), with operational lifetimes greater than 2 months, and shelf-life stability exceeding 6 months, under a wide variety of environmental conditions.

Source: FBO.gov

Tags: AwardsCBRN EquipmentMobile Response

Related Posts

Rigel Awarded $16.5 Million from DoD for Phase 3 Trial of Fostamatinib in COVID-19 Patients
Funding News

Rigel Awarded $16.5 Million from DoD for Phase 3 Trial of Fostamatinib in COVID-19 Patients

January 30, 2021
Defense Threat Reduction Agency Awards $75M for Antibiotic Drug Development
Antimicrobial Resistance

Defense Threat Reduction Agency Awards $75M for Antibiotic Drug Development

January 26, 2021
Vaccine Approval Is Just The Beginning – Huge Production Challenges Await
Funding News

OHDSI Awarded $10M FDA Contract to Monitor Safety and Effectiveness of Vaccines, Biologics

December 1, 2020
Virginia Tech Awarded USDA Grant to Study Survival of SARS-CoV-2 on Food Supply Chain Surfaces
Biosurveillance

Virginia Tech Awarded USDA Grant to Study Survival of SARS-CoV-2 on Food Supply Chain Surfaces

November 5, 2020
Load More

Latest News

First Human Trial of COVID-19 Vaccine Finds it is Safe and Induces Rapid Immune Response

COVID-19 Vaccination: What We Can Learn From the Great Polio Vaccine Heist of 1959

February 24, 2021
Sign on street in Conakry that says Ebola in large letters

Why Ebola is Back in Guinea and Why the Response Must Be Different This Time

February 24, 2021
How Roald Dahl Became a Passionate Vaccine Advocate

How Roald Dahl Became a Passionate Vaccine Advocate

February 23, 2021
How Do We Know the COVID Vaccine Won’t Have Long-Term Side-Effects?

How Do We Know the COVID Vaccine Won’t Have Long-Term Side-Effects?

February 23, 2021

Upcoming Events

Mar 1
Virtual Event
All day

Rare Disease Day at NIH 2021 – Virtual Conference

Mar 2
Virtual Event
March 2 - March 5

Effectiveness of Non-Vaccine Influenza Control Measures

Mar 2
Virtual Event
4:00 pm - 6:00 pm

RNA Viruses: How They Do What They Do

Mar 2
Virtual Event
5:00 pm - 7:00 pm

COVID Seminar Series – Hindsight is 2020

Mar 4
Virtual Event
10:00 am - 1:30 pm

Vulnerabilities in U.S. Chemical Weapons Detection, Identification, and Tracing

View More
Tweets by GlobalBioD

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2021 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
    • All Events
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Subscribe

© 2021 Stemar Media Group LLC